BMS’s Bladder Cancer Program Sees Change In Fortunes With Opdivo Substudy Win
Executive Summary
A cohort of patients in CheckMate-901 eligible for cisplatin chemotherapy showed OS and PFS improvements, after the company reported negative results in PD-L1-positive patients last year.